Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
EndocrinologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Diabetes, obesity & metabolism
- Publicado em
- 17 fev 2017
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R Webb, Kamlesh Khunti, Melanie J Davies
Descritores MeSH
- Diabetes Mellitus, Type 2
- Immunoglobulin Fc Fragments
- Recombinant Fusion Proteins
- Incretins
- Glucagon-Like Peptide-1 Receptor Agonists
- Glucagon-Like Peptides
- Hypoglycemic Agents
- Drug Administration Schedule
- Humans
- Glycated Hemoglobin
Veja também
Estudos relacionados
- Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
- Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis
- Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model